GABPB1-IT1: A Potential Drug Target and Biomarker (G55056)

Target Name: GABPB1-IT1

NCBI ID: G55056

GABPB1-IT1

Other Name(s): GABPB1 intronic transcript

GABPB1-IT1: A Potential Drug Target and Biomarker

GABPB1-IT1, also known as GABPB1, is a gene that encodes for a protein involved in the regulation of neurotransmitter release in the central nervous system (CNS). The GABPB1 gene has been implicated in various neurological disorders, including epilepsy, anxiety, and depression. GABPB1-IT1 has also been shown to play a role in the development of certain brain tumors. As a result, GABPB1-IT1 has emerged as a promising drug target and biomarker for a variety of neurological conditions.

GABPB1-IT1 function

GABPB1 is a member of the GABPB1 family, which is known for its role in the regulation of GABA, a neurotransmitter that plays a crucial role in the brain. GABA is a inhibitory neurotransmitter that is involved in a variety of physiological processes, including anxiety, depression, and epilepsy. In addition, GABA is also involved in modulating the activity of other neurotransmitters, including dopamine and GABA itself.

GABPB1-IT1 is a 21-kDa protein that is predominantly expressed in the brain and spinal cord. It is composed of 121 amino acid residues and has a calculated pI of 12.97. GABPB1-IT1 is involved in the regulation of neurotransmitter release by interacting with several different protein targets, including syntaxin, a protein that is involved in the trafficking of neurotransmitters to the endoplasmic reticulum (ER).

GABPB1-IT1 has been shown to play a role in the regulation of neurotransmitter release in various brain regions, including the prefrontal cortex, basal ganglia, and cerebellum. In addition, GABPB1-IT1 has been shown to be involved in the development of certain brain tumors, including neuroblastoma.

Drug targeting

GABPB1-IT1 has emerged as a promising drug target due to its involvement in the regulation of neurotransmitter release and its association with various neurological disorders. One approach to targeting GABPB1-IT1 is to use small molecules that can modulate its activity.

One of the most promising small molecules for targeting GABPB1-IT1 is a compound called N-Acetyl-L-Tyrosine (NAT). NAT is an amino acid that can modulate the activity of GABA receptors, including GABPB1-IT1. In addition, NAT has been shown to have neuroprotective properties and to be involved in the treatment of various neurological disorders, including epilepsy and anxiety.

Another small molecule that has been shown to interact with GABPB1-IT1 is called Alcidonin A-2 (ALC2). ALC2 is a peptide that can interact with GABPB1-IT1 and has been shown to modulate its activity. In addition, ALC2 has been shown to have neuroprotective properties and to be involved in the treatment of various neurological disorders, including epilepsy and neurodegenerative diseases.

Biomarker potential

GABPB1-IT1 has also been shown to be involved in the regulation of neurotransmitter release, which makes it an attractive biomarker for the diagnosis and treatment of various neurological disorders. One approach to using GABPB1-IT1 as a biomarker is to use techniques such as RNA sequencing (RNA-seq) to identify differentially expressed genes in the brain that are involved in the regulation of neurotransmitter release.

In addition, GABPB1-IT1 has also been shown to play a role in the regulation of neurotransmitter release in various brain regions, including the prefrontal cortex, basal ganglia, and cerebellum. This makes it an attractive candidate for use as a biomarker for the diagnosis and treatment of disorders that affect these regions, such as Parkinson's disease and Huntington's disease.

Conclusion

GABPB1-IT1 is a protein that is involved in the regulation of neurotransmitter release in the CNS. Its involvement in the regulation of neurotransmitter release has led to its potential as a drug target and biomarker for a variety of neurological disorders. The use of small molecules such as NAT and ALC2 has been shown to modulate GABPB1-IT1 activity, while its association with the development of certain brain tumors makes it an attractive candidate for targeted therapies. In addition, its involvement in the regulation of neurotransmitter release in various brain regions makes it an attractive candidate for use as a biomarker for the diagnosis and treatment of disorders that affect these regions. Further research is needed to fully understand the role of GABPB1-IT1 in the regulation of neurotransmitter release and its potential as a drug target and biomarker.

Protein Name: GABPB1 Intronic Transcript

The "GABPB1-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GABPB1-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets